Pub Date : 2018-01-01DOI: 10.4172/2157-2518.1000327
S. Santos-Filho
Prostate cancer is the most frequent tumor found in men worldwide and in Brazil and represents their secondleading cause of cancer-related death. Metastatic disease is largely resistant to conventional chemotherapies, and targeted therapies are urgently needed. The PSA (Prostate-Specific Antigen) blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. Prostate-Specific Membrane Antigen (PSMA) is a prototypical cell-surface marker of prostate cancer. PSMA is expressed in the neo-vascular of other solid tumours. This work aims to reach the publications of therapies utilized to treat prostatic cancer, mainly the physiotherapy, used to facilitate the life of patients with this disease. PubMed and World-Wide Science databases were used to screening about prostatic cancer therapies and biomarkers. The results showed that cryo-therapy and pelvic floor exercises were useful by physiotherapy to treat prostatic cancer. Chemotherapy showed to be the better treatment for this type of cancer. Though PSMA is a biomarker used in researches in the last 20 years, the PSA levels is still the best biomarker dosed in our days.
{"title":"Clinical Approaches in Prostate Cancer Therapies","authors":"S. Santos-Filho","doi":"10.4172/2157-2518.1000327","DOIUrl":"https://doi.org/10.4172/2157-2518.1000327","url":null,"abstract":"Prostate cancer is the most frequent tumor found in men worldwide and in Brazil and represents their secondleading cause of cancer-related death. Metastatic disease is largely resistant to conventional chemotherapies, and targeted therapies are urgently needed. The PSA (Prostate-Specific Antigen) blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. Prostate-Specific Membrane Antigen (PSMA) is a prototypical cell-surface marker of prostate cancer. PSMA is expressed in the neo-vascular of other solid tumours. This work aims to reach the publications of therapies utilized to treat prostatic cancer, mainly the physiotherapy, used to facilitate the life of patients with this disease. PubMed and World-Wide Science databases were used to screening about prostatic cancer therapies and biomarkers. The results showed that cryo-therapy and pelvic floor exercises were useful by physiotherapy to treat prostatic cancer. Chemotherapy showed to be the better treatment for this type of cancer. Though PSMA is a biomarker used in researches in the last 20 years, the PSA levels is still the best biomarker dosed in our days.","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"35 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80862943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The mutations of isocitrate dehydrogenase (IDH-mt) and loss of chromosome 1p and 19q (1p/19q codeleltion) have been used in diagnosis of gliomas, especially in identification of oligodendrocytoma. We have performed and analyzed genetic detections with 3 types of gliomas diagnosed by morphological methods. Methods: The DNA extracted from tumor tissues of 136 patients with astrocytoma, oligodendrogliomas and mixed gliomas were subjected to fluorescence PCR capillary electrophoresis for detection of 1p and 19q codeletion and DNA sequencing for IDH mutations. The results were analyzed by SPSS 22.0 software with chi-square test for significant difference (p<0.05). Results: Among 136 patients, 77 cases (56.6%) were histopathologically diagnosed as astrocytoma (AA, WHO ), 11 (8.0%) as pure oligodendroglial tumors including both low-grade oligodendrogliomas (OA, WHO ) and anaplastic oligodendrogliomas (AOA, WHO ), and 48 (35.4%) as mixed glioma with the features of OA and AA in the same tumor tissue. The genetic detections have shown that 39 cases (28.7%) were with IDH mutations (37 IDH1-mt p.R132H and 2 IDH2-mt), and 47 (34.6%) with 1p/19q co-deletion. The significant differences of the IDH mt (p=0.008) and 1p/19q codeletion (p=0.011) were between 3 pathological types of astrocytoma, oligodendrogliomas and mixed glioms (p=0.008). In three glioma types, the rate of 1p/19q co-deletion was highest in the group of oligodendrogliomas (p=0.040). In 11 patients who were histopathologically diagnosed as oligodendroglioma, only 5 cases meet the WHO criterion that requires the presence of both 1p/19q codeletion and IDH1-mt or IDH2-mt. Conclusion: The rate of IDH mutations and 1p/19q codeletion is significantly different in three groups of gliomas, and highest in oligodendrogliomas. Some cases of oligodendrogliomas with only IDH mutation but without 1p/19q codeletion. Therefore, the genetic detections should be complemented for diagnosis of gliomas.
{"title":"Different IDH Mutation and 1p/19q Codeletion Rates between Astrocytoma, Oligodendrocytoma and Mixed Gliomas","authors":"Jingchi Sun, Zhen Wang, Qiang Liu, Xinyong Huang, Zaihua Xu","doi":"10.4172/2157-2518.1000316","DOIUrl":"https://doi.org/10.4172/2157-2518.1000316","url":null,"abstract":"Background: The mutations of isocitrate dehydrogenase (IDH-mt) and loss of chromosome 1p and 19q (1p/19q codeleltion) have been used in diagnosis of gliomas, especially in identification of oligodendrocytoma. We have performed and analyzed genetic detections with 3 types of gliomas diagnosed by morphological methods. Methods: The DNA extracted from tumor tissues of 136 patients with astrocytoma, oligodendrogliomas and mixed gliomas were subjected to fluorescence PCR capillary electrophoresis for detection of 1p and 19q codeletion and DNA sequencing for IDH mutations. The results were analyzed by SPSS 22.0 software with chi-square test for significant difference (p<0.05). Results: Among 136 patients, 77 cases (56.6%) were histopathologically diagnosed as astrocytoma (AA, WHO ), 11 (8.0%) as pure oligodendroglial tumors including both low-grade oligodendrogliomas (OA, WHO ) and anaplastic oligodendrogliomas (AOA, WHO ), and 48 (35.4%) as mixed glioma with the features of OA and AA in the same tumor tissue. The genetic detections have shown that 39 cases (28.7%) were with IDH mutations (37 IDH1-mt p.R132H and 2 IDH2-mt), and 47 (34.6%) with 1p/19q co-deletion. The significant differences of the IDH mt (p=0.008) and 1p/19q codeletion (p=0.011) were between 3 pathological types of astrocytoma, oligodendrogliomas and mixed glioms (p=0.008). In three glioma types, the rate of 1p/19q co-deletion was highest in the group of oligodendrogliomas (p=0.040). In 11 patients who were histopathologically diagnosed as oligodendroglioma, only 5 cases meet the WHO criterion that requires the presence of both 1p/19q codeletion and IDH1-mt or IDH2-mt. Conclusion: The rate of IDH mutations and 1p/19q codeletion is significantly different in three groups of gliomas, and highest in oligodendrogliomas. Some cases of oligodendrogliomas with only IDH mutation but without 1p/19q codeletion. Therefore, the genetic detections should be complemented for diagnosis of gliomas.","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88959151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01Epub Date: 2018-03-26DOI: 10.4172/2157-2518.1000312
Asserewou Etekpo, Ahmad Alghawalby, Marwa Alghawalby, Amr S Soliman, Ahmed Hablas, Baojiang Chen, Surinder Batra, Ghada A Soliman
Pancreatic cancer is the fourth cause of cancer deaths in the U.S. with most patients diagnosed at advanced stages followed by short survival. Therefore, biomarkers for early detection are urgently needed. Mucin 4 (MUC4) is a mucin protein encoded by the MUC4 gene and identified in the majority of pancreatic cancers. With increasing clinical identification and diagnosis of pancreatic cysts globally and transformation of some cysts into pancreatic cancer, it is important to evaluate if MUC4 is expressed in pancreatic cysts. Immunohistochemistry assays utilizing heat-induced epitope retrieval (HIER) were performed to examine MUC4 protein expression in 44 paraffin-embedded tissues of pancreatic cancers and 20 pancreatic cysts. All patients were diagnosed and operated upon at the Mansoura University Gastrointestinal Surgery Center in Egypt. Clinical, demographic, and survival information were abstracted from the patients' medical records. Logistic regression was performed to predict expression of MUC4 protein in cancer and cysts, by type of cysts. Pancreatic cyst patients were significantly younger than pancreatic cancer patients (Mean age of 28.7 ± 5.25 vs. 54.84 ± 10.60 years) (p=0.0001). Expression of MUC4 was not different between cancers and pancreatic cysts (p=0.16). However, type of pancreatic cysts was predictive of MUC4 expression. Mucinous cystic neoplasms and serous cystadenoma cysts showed significantly higher MUC4 expression than non-specified and pseudocysts (80%, 75%, 25%, and 0% expression for the 4 types of cysts, respectively) (p=0.022). MUC4 expression may be associated with certain types of cysts. Follow-up of pancreatic cyst patients who show MUC4 expression might reveal clues to early detection of pancreatic cancer.
{"title":"Differences in <i>MUC4</i> Expression in Pancreatic Cancers and Pancreatic Cysts in Egypt.","authors":"Asserewou Etekpo, Ahmad Alghawalby, Marwa Alghawalby, Amr S Soliman, Ahmed Hablas, Baojiang Chen, Surinder Batra, Ghada A Soliman","doi":"10.4172/2157-2518.1000312","DOIUrl":"https://doi.org/10.4172/2157-2518.1000312","url":null,"abstract":"<p><p>Pancreatic cancer is the fourth cause of cancer deaths in the U.S. with most patients diagnosed at advanced stages followed by short survival. Therefore, biomarkers for early detection are urgently needed. Mucin 4 (<i>MUC4</i>) is a mucin protein encoded by the <i>MUC4</i> gene and identified in the majority of pancreatic cancers. With increasing clinical identification and diagnosis of pancreatic cysts globally and transformation of some cysts into pancreatic cancer, it is important to evaluate if <i>MUC4</i> is expressed in pancreatic cysts. Immunohistochemistry assays utilizing heat-induced epitope retrieval (HIER) were performed to examine <i>MUC4</i> protein expression in 44 paraffin-embedded tissues of pancreatic cancers and 20 pancreatic cysts. All patients were diagnosed and operated upon at the Mansoura University Gastrointestinal Surgery Center in Egypt. Clinical, demographic, and survival information were abstracted from the patients' medical records. Logistic regression was performed to predict expression of <i>MUC4</i> protein in cancer and cysts, by type of cysts. Pancreatic cyst patients were significantly younger than pancreatic cancer patients (Mean age of 28.7 ± 5.25 <i>vs.</i> 54.84 ± 10.60 years) (p=0.0001). Expression of <i>MUC4</i> was not different between cancers and pancreatic cysts (p=0.16). However, type of pancreatic cysts was predictive of <i>MUC4</i> expression. Mucinous cystic neoplasms and serous cystadenoma cysts showed significantly higher <i>MUC4</i> expression than non-specified and pseudocysts (80%, 75%, 25%, and 0% expression for the 4 types of cysts, respectively) (p=0.022). <i>MUC4</i> expression may be associated with certain types of cysts. Follow-up of pancreatic cyst patients who show <i>MUC4</i> expression might reveal clues to early detection of pancreatic cancer.</p>","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39102889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2157-2518.1000314
E. Adankwah, K. O. Danquah, Daniel Gyamfi, P. Ossei, E. Asiamah, Ibrahim A. Alsafari, T. Madgwick
Background: Autophagy is an important biological process that is involved in cellular homeostasis and survival. Derailment of some cellular autophagic processes affects normal cellular function, resulting in cancers and other disorders. Autophagy related proteins are Beclin-1, a human tumour suppressor, Bcl-2 and p62 have been characterised in most cancers. Particularly, a number of studies have reported a loss of Beclin-1 and up regulation of Bcl-2 and p62 in breast cancers. However, studies regarding the expression of these proteins in colorectal adenomaadenocarcinoma transformation sequence are yet to be described. In this study, we examined the expression patterns of Beclin-1, Bcl-2 and p62 in both colorectal adenomas and adenocarcinomas. Methods: Immunohistochemistry was performed on formalin-fixed paraffin embedded tissue sections from 14 patients with colorectal tumours and the expression patterns were semi-quantitatively evaluated based on the intensity of staining and the percentage of tumour cells stained. Results: Cytoplasmic Beclin-1 and p62 expression patterns ranged from moderate to high in both tubular adenomas and adenocarcinomas as compared to normal colonic mucosa. Cytoplasmic Bcl-2 expression was moderately expressed in tubular adenomas but negative to low expression was observed in the adenocarcinomas. This study also provided, for the first time, nuclear localization of p62 in only the colorectal adenocarcinomas. Conclusion: Beclin-1, Bcl-2 and p62 may be up regulated in the transition of colorectal adenomas to adenocarcinomas.
{"title":"Nuclear Localisation of Autophagic p62 and Associated Cytoplasmic Beclin-1 and Bcl-2 Expressions in Adenomas and Adenocarcinomas of the Colorectal Regions","authors":"E. Adankwah, K. O. Danquah, Daniel Gyamfi, P. Ossei, E. Asiamah, Ibrahim A. Alsafari, T. Madgwick","doi":"10.4172/2157-2518.1000314","DOIUrl":"https://doi.org/10.4172/2157-2518.1000314","url":null,"abstract":"Background: Autophagy is an important biological process that is involved in cellular homeostasis and survival. Derailment of some cellular autophagic processes affects normal cellular function, resulting in cancers and other disorders. Autophagy related proteins are Beclin-1, a human tumour suppressor, Bcl-2 and p62 have been characterised in most cancers. Particularly, a number of studies have reported a loss of Beclin-1 and up regulation of Bcl-2 and p62 in breast cancers. However, studies regarding the expression of these proteins in colorectal adenomaadenocarcinoma transformation sequence are yet to be described. In this study, we examined the expression patterns of Beclin-1, Bcl-2 and p62 in both colorectal adenomas and adenocarcinomas. Methods: Immunohistochemistry was performed on formalin-fixed paraffin embedded tissue sections from 14 patients with colorectal tumours and the expression patterns were semi-quantitatively evaluated based on the intensity of staining and the percentage of tumour cells stained. Results: Cytoplasmic Beclin-1 and p62 expression patterns ranged from moderate to high in both tubular adenomas and adenocarcinomas as compared to normal colonic mucosa. Cytoplasmic Bcl-2 expression was moderately expressed in tubular adenomas but negative to low expression was observed in the adenocarcinomas. This study also provided, for the first time, nuclear localization of p62 in only the colorectal adenocarcinomas. Conclusion: Beclin-1, Bcl-2 and p62 may be up regulated in the transition of colorectal adenomas to adenocarcinomas.","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"57 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90177036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2157-2518.1000322
D. Euhus, D. Bu, M. Considine, L. Cope
{"title":"Molecular Evolution of Spontaneously Immortalizing Human Mammary Epithelial Cells from a Woman with a Germline STK11 Mutation","authors":"D. Euhus, D. Bu, M. Considine, L. Cope","doi":"10.4172/2157-2518.1000322","DOIUrl":"https://doi.org/10.4172/2157-2518.1000322","url":null,"abstract":"","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87232376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2157-2518.1000317
Y. Yakushijin
Follicular lymphoma (FL), which originates in germinal center B-lymphocytes, has been recognized to be a heterogeneous entity in some patients developing progressive or transformed diseases. Secondary genetic events after t(14;18) translocation have been associated with this histological transformation, such as c-myc amplification and/or translocation. Activation-induced cytidine deaminase (AID/AICDA) is required for somatic hyper-mutation and class switch recombination of immunoglobulin genes, and c-myc translocation of the germinal centre derived B-cell lymphoma. The role of AID in FL pathogenesis has not been established. Here we tried to identify the significance of AID associated with c-myc in the progression of FL, and showed that switched-off AID or a low expression of AID after c-myc amplification might correlate to rapidly progressive FL as well as to overall clinical outcomes.
{"title":"Optimal Use of Biomarkers in Oncology: Expression of Activation-induced Cytidine Deaminase (AID/AICDA) in Follicular Lymphoma","authors":"Y. Yakushijin","doi":"10.4172/2157-2518.1000317","DOIUrl":"https://doi.org/10.4172/2157-2518.1000317","url":null,"abstract":"Follicular lymphoma (FL), which originates in germinal center B-lymphocytes, has been recognized to be a heterogeneous entity in some patients developing progressive or transformed diseases. Secondary genetic events after t(14;18) translocation have been associated with this histological transformation, such as c-myc amplification and/or translocation. Activation-induced cytidine deaminase (AID/AICDA) is required for somatic hyper-mutation and class switch recombination of immunoglobulin genes, and c-myc translocation of the germinal centre derived B-cell lymphoma. The role of AID in FL pathogenesis has not been established. Here we tried to identify the significance of AID associated with c-myc in the progression of FL, and showed that switched-off AID or a low expression of AID after c-myc amplification might correlate to rapidly progressive FL as well as to overall clinical outcomes.","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"117 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79078998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2157-2518.1000E124
D. Padmaja, Pratheeshkumar Poyil
Patient Derived Organoids (PDOs) are described as miniature, three dimensional (3D) cell cultures prepared from patient’s cancer cell to compare therapeutic responses in the laboratory and clinical settings. Personalized cancer medicine is a novel therapeutic strategy to identify a right treatment for the right patient in accordance with tumor’s genetic signature. Tumor Organoid models have innumerable benefits over pre-existing models which makes them a tremendous candidate in personalized cancer therapy as they mimic the physiology of the original tumor. Recently several studies have shown the value of these “tumor in-dish” approaches in personalized cancer medicine for preclinical drug screening and prediction of patient treatment outcome. The objective of this “Journal of Carcinogenesis and Mutagenesis” research topic is to advance our current understanding about PDOs as an attractive in vitro model system for studying tumor evolution and response to drugs and treatments.
{"title":"Patient-Derived Tumor Organoids: A Promising Tool for Personalized Cancer Therapy","authors":"D. Padmaja, Pratheeshkumar Poyil","doi":"10.4172/2157-2518.1000E124","DOIUrl":"https://doi.org/10.4172/2157-2518.1000E124","url":null,"abstract":"Patient Derived Organoids (PDOs) are described as miniature, three dimensional (3D) cell cultures prepared from patient’s cancer cell to compare therapeutic responses in the laboratory and clinical settings. Personalized cancer medicine is a novel therapeutic strategy to identify a right treatment for the right patient in accordance with tumor’s genetic signature. Tumor Organoid models have innumerable benefits over pre-existing models which makes them a tremendous candidate in personalized cancer therapy as they mimic the physiology of the original tumor. Recently several studies have shown the value of these “tumor in-dish” approaches in personalized cancer medicine for preclinical drug screening and prediction of patient treatment outcome. The objective of this “Journal of Carcinogenesis and Mutagenesis” research topic is to advance our current understanding about PDOs as an attractive in vitro model system for studying tumor evolution and response to drugs and treatments.","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"32 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74003280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2157-2518.1000324
D. Bursac
{"title":"Safely Chemotherapy Administration in Patient with Small-cell Lung Cancer and End-stage Renal Disease Undergoing Haemodialysis","authors":"D. Bursac","doi":"10.4172/2157-2518.1000324","DOIUrl":"https://doi.org/10.4172/2157-2518.1000324","url":null,"abstract":"","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"57 6-7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78115377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2157-2518.1000320
B. M. T. Gorish, Humodi Ahmed Saeed Supervisor
{"title":"Frequency of HBV among Hepatocellular Carcinoma Patients in Khartoum State, Sudan","authors":"B. M. T. Gorish, Humodi Ahmed Saeed Supervisor","doi":"10.4172/2157-2518.1000320","DOIUrl":"https://doi.org/10.4172/2157-2518.1000320","url":null,"abstract":"","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81980983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2157-2518.1000326
K. Fujioka
{"title":"Presentations of Clinical, Ultrasonographic and Pathological Features of Nodular Fasciitis from an Established Cytogenetic Viewpoint: Review of the Case Series","authors":"K. Fujioka","doi":"10.4172/2157-2518.1000326","DOIUrl":"https://doi.org/10.4172/2157-2518.1000326","url":null,"abstract":"","PeriodicalId":15209,"journal":{"name":"Journal of carcinogenesis & mutagenesis","volume":"100 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75605507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：